Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____ to _____ Commission File Number 000-23186 BIOCRYST PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) (State or other jurisdict ...

BioCryst Pharmaceuticals (BCRX) came out with quarterly earnings of $1.12 per share, beating the Zacks Consensus Estimate of $0.07 per share. This compares to a loss of $0.13 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +1,623.08%. A quarter ago, it was expected that this drugmaker would post earnings of $0.07 per share when it actually produced earnings of $0.06, delivering a surprise of -14.29%.Over the last four quarters ...

BioCryst Pharmaceuticals (NasdaqGS:BCRX) Q4 2025 Earnings call February 26, 2026 08:30 AM ET Company ParticipantsBabar Ghias - Chief Financial Officer and Head of Corporate DevelopmentBill Sheridan - Chief Development OfficerBrian Abrahams - Managing DirectorCharlie Gayer - President and CEOLaura Chico - Managing Director, Equity ResearchMikaela Vanik - Research AssociateNick Wilder - Manager, Investor RelationsConference Call ParticipantsNone - AnalystNone - AnalystNone - AnalystNone - AnalystOperatorWelco ...

Full Year 2025 Results Call Corporate Update & Financial Results February 26, 2026 CONFIDENTIAL & PROPRIETARY Forward-looking statements This presentation contains forward-looking statements, including statements regarding, among other things, future results, performance or achievements, expectations regarding pipeline development, anticipated approval and commercialization of navenibart, pharmaceutical research and development, such as drug discovery, preclinical and clinical development activities and rel ...

Revenue Performance - Preliminary, unaudited ORLADEYO net revenue for Q4 2025 was $151 million, representing a 22% year-over-year increase and a 36% increase on a comparable basis, excluding European ORLADEYO revenue for Q4 2024[12] - Preliminary, unaudited ORLADEYO net revenue for the full year 2025 was $601 million, reflecting a 37% year-over-year growth; excluding European ORLADEYO revenue, the net revenue was $563 million, marking a 43% increase on a comparable basis[12] Financial Position - As of December 31, 2025, the company reported preliminary, unaudited cash, cash equivalents, restricted cash, and investments totaling $338 million[12]

—Full year 2025 ORLADEYO® net revenue of $601.8 million (+38% y-o-y; +43% y-o-y excluding European ORLADEYO revenue following the sale of the European ORLADEYO business to Neopharmed Gentili S.p.A. on October 1, 2025)— —Record GAAP and non-GAAP operating profit for full year 2025— —Maintained full year 2026 ORLADEYO revenue guidance between $625 and $645 million— —Received FDA approval for ORLADEYO oral pellets for patients with HAE Aged 2 to <12 Years— —Completed Acquisition of Astria Therapeutics— RESEARC ...

Core Insights - BioCryst Pharmaceuticals will present nine abstracts from its hereditary angioedema (HAE) portfolio at the 2026 AAAAI Annual Meeting in Philadelphia from February 27 to March 2, 2026 [1][2] HAE Portfolio Developments - Six abstracts will focus on new clinical trial and real-world outcomes with ORLADEYO (berotralstat), the first targeted oral prophylactic therapy for HAE patients aged 2 and older [2] - Three abstracts will present new clinical trial outcomes with navenibart, a long-acting monoclonal antibody plasma kallikrein inhibitor [2] - A late-breaking presentation will highlight positive interim results from the ALPHA-SOLAR trial, showing sustained HAE attack suppression with navenibart administered every 3 or 6 months [2][4] Strategic Focus - The data presented reflects BioCryst's strategy to expand and diversify its HAE portfolio, aiming to provide meaningful treatment options that align with patient needs [3] - The company is advancing programs like navenibart and launching an expanded pediatric indication for ORLADEYO [3] Presentation Details - BioCryst will present eight posters on February 27, 2026, and one late-breaking abstract on March 1, 2026, at the Convention Center, Level 2, Hall E [4] Product Information - ORLADEYO (berotralstat) is the first oral therapy specifically designed to prevent HAE attacks in patients aged 2 years and older [5] - Navenibart is an investigational monoclonal antibody being evaluated for long-term prevention of HAE attacks, with potential dosing every 3 or 6 months [6] Research Findings - Interim data from the APeX-P trial indicates that oral berotralstat reduces the rate of moderate and severe attacks in children aged 2 to less than 12 years [7] - Various posters will present real-world evidence on the impact of berotralstat on attack rates and healthcare resource utilization among patients with C1-inhibitor deficiency [7]

Company Overview - BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) specializes in treatments for rare diseases, including an oral medication for hereditary angioedema and an injectable flu therapy [3] - The company is also engaged in discovering and testing new drugs for allergic and immunological conditions [3] Recent Developments - On January 23, BioCryst finalized a $700 million acquisition of Astria Therapeutics, which adds navenibart to its portfolio [3] - Navenibart is a long-acting Phase 3 therapy for hereditary angioedema, a rare genetic condition causing sudden, painful swelling [3] Market Sentiment - Jim Cramer expressed a negative outlook on BioCryst, advising investors to stay away from the stock, indicating it has been underperforming for a long time [1] - There is a belief that certain AI stocks may offer greater upside potential and carry less downside risk compared to BioCryst [4]

Group 1 - BioCryst Pharmaceuticals will report its fourth quarter 2025 financial results on February 26, 2026 [1] - A conference call and webcast will be hosted by BioCryst management at 8:30 a.m. ET on the same day to discuss the financial results and provide a corporate update [1] - The live call can be accessed by domestic and international callers through specific phone numbers, and a live webcast will be available on the company's website [2] Group 2 - BioCryst is a global biotechnology company focused on developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases [3] - The company has commercialized ORLADEYO® (berotralstat), the first oral, once-daily plasma kallikrein inhibitor, and is advancing a pipeline of potential first-in-class or best-in-class therapeutics [3]

Core Insights - BioCryst Pharmaceuticals has completed the acquisition of Astria Therapeutics, enhancing its leadership in hereditary angioedema (HAE) and supporting long-term growth [1][5] Acquisition Details - The acquisition was valued at approximately $700 million, financed through cash on hand and a financing facility, with BioCryst issuing about 37.3 million shares to Astria's equity holders [5] Product Portfolio Enhancement - BioCryst adds navenibart, a late-stage plasma kallikrein inhibitor in Phase 3 development, which could be the first HAE therapy with every-three and every-six month dosing, improving patient treatment experiences [2][3] - The company now offers both the leading oral therapy (ORLADEYO®) and a potentially best-in-class injectable option, providing optimal choices for individualized patient care [3] Strategic Leadership Changes - Jill C. Milne, Ph.D., co-founder and CEO of Astria, has joined BioCryst's Board of Directors, while John Ruesch has been appointed as Chief Technical Operations Officer, bringing expertise in product development [6] Additional Programs - BioCryst has acquired Astria's early-stage program for atopic dermatitis, STAR0310, and plans to explore strategic alternatives for this program [4]